Zacks: Brokerages Anticipate Trevena, Inc. (NASDAQ:TRVN) to Post -$0.10 EPS

Wall Street brokerages expect that Trevena, Inc. (NASDAQ:TRVNGet Rating) will post ($0.10) earnings per share for the current quarter, according to Zacks Investment Research. Two analysts have provided estimates for Trevena’s earnings. The highest EPS estimate is ($0.09) and the lowest is ($0.10). Trevena posted earnings of ($0.09) per share in the same quarter last year, which suggests a negative year-over-year growth rate of 11.1%. The firm is expected to issue its next earnings results on Monday, January 1st.

On average, analysts expect that Trevena will report full year earnings of ($0.37) per share for the current financial year, with EPS estimates ranging from ($0.40) to ($0.32). For the next financial year, analysts expect that the business will report earnings of ($0.32) per share, with EPS estimates ranging from ($0.36) to ($0.27). Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side research firms that cover Trevena.

Trevena (NASDAQ:TRVNGet Rating) last posted its quarterly earnings results on Wednesday, May 11th. The biopharmaceutical company reported ($0.10) EPS for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.01). Trevena had a negative return on equity of 74.90% and a negative net margin of 7,771.74%. During the same period in the prior year, the firm posted ($0.06) EPS.

Several brokerages have issued reports on TRVN. StockNews.com began coverage on shares of Trevena in a research report on Saturday, May 7th. They set a “sell” rating for the company. HC Wainwright cut their price objective on shares of Trevena from $5.00 to $3.50 in a research report on Thursday. Finally, Zacks Investment Research upgraded shares of Trevena from a “sell” rating to a “hold” rating in a research report on Wednesday, February 2nd.

Trevena stock traded down $0.01 during midday trading on Monday, reaching $0.20. 1,664,453 shares of the company’s stock were exchanged, compared to its average volume of 1,338,691. Trevena has a 52 week low of $0.18 and a 52 week high of $2.20. The stock’s 50-day simple moving average is $0.39 and its 200 day simple moving average is $0.56.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. BNP Paribas Arbitrage SA raised its position in Trevena by 454.1% during the third quarter. BNP Paribas Arbitrage SA now owns 34,896 shares of the biopharmaceutical company’s stock valued at $43,000 after purchasing an additional 28,598 shares in the last quarter. Bank of America Corp DE raised its position in Trevena by 48.1% during the second quarter. Bank of America Corp DE now owns 34,607 shares of the biopharmaceutical company’s stock valued at $59,000 after purchasing an additional 11,243 shares in the last quarter. Two Sigma Advisers LP acquired a new position in Trevena during the third quarter valued at approximately $60,000. Invesco Ltd. bought a new stake in shares of Trevena during the second quarter worth $73,000. Finally, Barclays PLC bought a new stake in shares of Trevena during the third quarter worth $83,000. Institutional investors own 21.20% of the company’s stock.

Trevena Company Profile (Get Rating)

Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV027 for the treatment of acute lung injury contributing to acute respiratory distress syndrome and abnormal blood clotting in patients with COVID-19; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.

Read More

Get a free copy of the Zacks research report on Trevena (TRVN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Trevena (NASDAQ:TRVN)

Receive News & Ratings for Trevena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena and related companies with MarketBeat.com's FREE daily email newsletter.